Literature DB >> 28637923

Infectivity of Plasmodium falciparum sporozoites determines emerging parasitemia in infected volunteers.

Matthew B B McCall1, Linda J Wammes1, Marijke C C Langenberg2, Geert-Jan van Gemert3, Jona Walk3, Cornelus C Hermsen3, Wouter Graumans3, Rob Koelewijn1,2, Jean-François Franetich4, Sandra Chishimba1, Max Gerdsen3, Audrey Lorthiois4, Marga van de Vegte3, Dominique Mazier4,5, Else M Bijker3, Jaap J van Hellemond1, Perry J J van Genderen2, Robert W Sauerwein6.   

Abstract

Malaria sporozoites must first undergo intrahepatic development before a pathogenic blood-stage infection is established. The success of infection depends on host and parasite factors. In healthy human volunteers undergoing controlled human malaria infection (CHMI), we directly compared three clinical Plasmodium falciparum isolates for their ability to infect primary human hepatocytes in vitro and to drive the production of blood-stage parasites in vivo. Our data show a correlation between the efficiency of strain-specific sporozoite invasion of human hepatocytes and the dynamics of patent parasitemia in study subjects, highlighting intrinsic differences in infectivity among P. falciparum isolates from distinct geographical locales. The observed heterogeneity in infectivity among strains underscores the value of assessing the protective efficacy of candidate malaria vaccines against heterologous strains in the CHMI model.
Copyright © 2017 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Entities:  

Mesh:

Year:  2017        PMID: 28637923     DOI: 10.1126/scitranslmed.aag2490

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   17.956


  22 in total

1.  The Controlled Human Malaria Infection Experience at the University of Maryland.

Authors:  DeAnna J Friedman-Klabanoff; Matthew B Laurens; Andrea A Berry; Mark A Travassos; Matthew Adams; Kathy A Strauss; Biraj Shrestha; Myron M Levine; Robert Edelman; Kirsten E Lyke
Journal:  Am J Trop Med Hyg       Date:  2019-03       Impact factor: 2.345

2.  A Potent Anti-Malarial Human Monoclonal Antibody Targets Circumsporozoite Protein Minor Repeats and Neutralizes Sporozoites in the Liver.

Authors:  Lawrence T Wang; Lais S Pereira; Yevel Flores-Garcia; James O'Connor; Barbara J Flynn; Arne Schön; Nicholas K Hurlburt; Marlon Dillon; Annie S P Yang; Amanda Fabra-García; Azza H Idris; Bryan T Mayer; Monica W Gerber; Raphael Gottardo; Rosemarie D Mason; Nicole Cavett; Reid B Ballard; Neville K Kisalu; Alvaro Molina-Cruz; Jorgen Nelson; Rachel Vistein; Carolina Barillas-Mury; Rogerio Amino; David Baker; Neil P King; Robert W Sauerwein; Marie Pancera; Ian A Cockburn; Fidel Zavala; Joseph R Francica; Robert A Seder
Journal:  Immunity       Date:  2020-09-17       Impact factor: 31.745

3.  Changes in total and differential leukocyte counts during the clinically silent liver phase in a controlled human malaria infection in malaria-naïve Dutch volunteers.

Authors:  Marlies E van Wolfswinkel; Marijke C C Langenberg; Linda J Wammes; Robert W Sauerwein; Rob Koelewijn; Cornelus C Hermsen; Jaap J van Hellemond; Perry J van Genderen
Journal:  Malar J       Date:  2017-11-10       Impact factor: 2.979

Review 4.  Engineered Livers for Infectious Diseases.

Authors:  Nil Gural; Liliana Mancio-Silva; Jiang He; Sangeeta N Bhatia
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2017-11-22

5.  Human antibodies activate complement against Plasmodium falciparum sporozoites, and are associated with protection against malaria in children.

Authors:  Liriye Kurtovic; Marije C Behet; Gaoqian Feng; Linda Reiling; Kiprotich Chelimo; Arlene E Dent; Ivo Mueller; James W Kazura; Robert W Sauerwein; Freya J I Fowkes; James G Beeson
Journal:  BMC Med       Date:  2018-04-30       Impact factor: 8.775

6.  The Complement System Contributes to Functional Antibody-Mediated Responses Induced by Immunization with Plasmodium falciparum Malaria Sporozoites.

Authors:  Marije C Behet; Liriye Kurtovic; Geert-Jan van Gemert; Celine M Haukes; Rianne Siebelink-Stoter; Wouter Graumans; Marga G van de Vegte-Bolmer; Anja Scholzen; Jeroen D Langereis; Dimitri A Diavatopoulos; James G Beeson; Robert W Sauerwein
Journal:  Infect Immun       Date:  2018-06-21       Impact factor: 3.441

7.  Generation of Novel Plasmodium falciparum NF135 and NF54 Lines Expressing Fluorescent Reporter Proteins Under the Control of Strong and Constitutive Promoters.

Authors:  Shinya Miyazaki; Annie S P Yang; Fiona J A Geurten; Catherin Marin-Mogollon; Yukiko Miyazaki; Takashi Imai; Surendra Kumar Kolli; Jai Ramesar; Severine Chevalley-Maurel; Ahmed M Salman; Geert-Jan A van Gemert; Youri M van Waardenburg; Blandine Franke-Fayard; Adrian V S Hill; Robert W Sauerwein; Chris J Janse; Shahid M Khan
Journal:  Front Cell Infect Microbiol       Date:  2020-06-10       Impact factor: 5.293

8.  Novel insights from the Plasmodium falciparum sporozoite-specific proteome by probabilistic integration of 26 studies.

Authors:  Lisette Meerstein-Kessel; Jeron Venhuizen; Daniel Garza; Nicholas I Proellochs; Emma J Vos; Joshua M Obiero; Philip L Felgner; Robert W Sauerwein; Marynthe Peters; Annie S P Yang; Martijn A Huynen
Journal:  PLoS Comput Biol       Date:  2021-04-30       Impact factor: 4.475

Review 9.  Next-Generation Human Liver Models for Antimalarial Drug Assays.

Authors:  Kasem Kulkeaw
Journal:  Antibiotics (Basel)       Date:  2021-05-27

10.  Modest heterologous protection after Plasmodium falciparum sporozoite immunization: a double-blind randomized controlled clinical trial.

Authors:  Jona Walk; Isaie J Reuling; Marije C Behet; Lisette Meerstein-Kessel; Wouter Graumans; Geert-Jan van Gemert; Rianne Siebelink-Stoter; Marga van de Vegte-Bolmer; Thorsten Janssen; Karina Teelen; Johannes H W de Wilt; Quirijn de Mast; André J van der Ven; Ernest Diez Benavente; Susana Campino; Taane G Clark; Martijn A Huynen; Cornelus C Hermsen; Else M Bijker; Anja Scholzen; Robert W Sauerwein
Journal:  BMC Med       Date:  2017-09-13       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.